China Biologic Products: Exclusive License Agreement with Sanofi for Rofasveltide

China Biopharmaceuticals issues a voluntary announcement. The company’s subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd., has entered into an exclusive licensing agreement with a wholly-owned subsidiary of Sanofi for the global development, manufacturing, and commercialization of the JAK/ROCK inhibitor Rova-T (brand name: Anxu). The company will receive an upfront payment of $135 million, milestone payments up to $1.395 billion, and tiered royalties based on annual net sales, with a maximum double-digit percentage. Rova-T is the world’s first oral small-molecule dual JAK/ROCK inhibitor. In February 2026, it was approved by China’s National Medical Products Administration (NMPA) for first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis. It has entered Phase III clinical trials in China for chronic graft-versus-host disease (cGVHD) and has been included in the Breakthrough Therapy Designation by CDE; in the U.S., Phase II clinical trials have been approved, with Ib/IIa data published in the journal Blood. This licensing marks a major breakthrough in the company’s global innovative drug strategy, potentially significantly increasing future revenue and profits, and strengthening the company’s international competitiveness in hematologic tumors and immunofibrosis fields.